Researchers from Jagiellonian University presented the discovery of novel multifunctional inhibitors of phosphodiesterases (PDEs) and transient receptor potential ankyrin 1 (TRPA1) antagonists as potential therapeutic candidates for the treatment for chronic airway disorders.
Autosomal dominant hypocalcemia (ADH) type 1 and 2 are disorders that affect calcium homeostasis caused by gain-of-function mutations in CaSR, which encodes the calcium-sensing receptor.
Researchers from Consejo Superior de Investigaciones Cientificas (CSIC) and affiliated organizations presented the discovery of a novel series of compounds acting as Ebola virus (EBOV) entry inhibitors.
A series of novel tacrine derivatives acting as acetylcholinesterase inhibitors and N-methyl-D-aspartate (NMDA) receptor subtype antagonists has been developed in research seeking to exploit these targets for the treatment of Alzheimer's disease.
Researchers from the University of Santiago de Compostela and University of Porto have reported the discovery of a novel acetylcholinesterase (AChE) inhibitor, MJM-255.
Iama Therapeutics Srl has sought new, selective inhibitors of solute carrier family 12 member 2 (NKCC1) to treat autism, Down syndrome and brain disorders featuring chloride (NKCC1/solute carrier family 12 member 5 [KCC2]) imbalance.
